Compare General Motors Company (GM) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Incyte Corporation — how do they compare? General Motors Company trades at $82.73 (market cap $72.17B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: General Motors Company is far larger — about 3.2× Incyte Corporation's market cap, and General Motors Company pays a 0.88% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Incyte Corporation for 33 Days on average.
| GM | INCY | |
|---|---|---|
Market Cap | $72.17B | $22.85B |
Volume | 4,900,304 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $129.93 |
52-Week Low | $55.35 | $83.80 |
Typical Hold Time | 83 Days | 33 Days |
Enterprise Value | $175.15B | $18.35B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.25, up 1.56% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong cash flow ($26.9B operating cash flow in 2025) but declining profit margins (1.05% net margin). Recent Q3 2026 sales declined 5.5% as EV demand weakens, though regulatory savings of $20.4B through 2031 provide some offset. Analyst consensus remains bullish with a $102.08 price target representing 24% upside potential.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but long-term value exists through cost savings initiatives and strong cash generation. The stock trades at attractive valuations (P/S 0.42x) with 67% analyst buy ratings, though competitive pressure from Asian automakers and EV transition challenges present significant execution risks for investors.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
